MFSD2A and hepatocellular carcinoma: Overall, MFSD2A was positively and negatively expressed in 71 (89.9%) and 8 (10.1%) of the 79 HCC patients, respectively (Figure 2A–2C, total score ≥ 1; Figure 2D, total score = 0).